Cargando…
Myositis associated to COVID-19 mimics an acute exacerbation in myasthenia gravis patient
Autores principales: | De Martino, Antonio, Barone, Stefania, Santangelo, Domenico, Magro, Giuseppe, Tosto, Federico, Pascarella, Angelo, Manzo, Lucia, Bruno, Pietro, Pasquale, Marilisa, Valentino, Paola, Gambardella, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498526/ http://dx.doi.org/10.1016/j.jns.2021.119865 |
Ejemplares similares
-
End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab
por: Magro, Giuseppe, et al.
Publicado: (2021) -
Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
por: Magro, Giuseppe, et al.
Publicado: (2022) -
A case of neuromyelitis optica spectrum disorder (NMOSD) and acute myositis following SARS-CoV-2 infection
por: Barone, Stefania, et al.
Publicado: (2021) -
Granulomatous Myositis Associated with Myasthenia Gravis: A Rare Case
por: Iqbal, Shumaila M, et al.
Publicado: (2019) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021)